Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 6/2014

01.12.2014 | REVIEW ARTICLE

Roles of Obese-Insulin Resistance and Anti-Diabetic Drugs on the Heart with Ischemia-Reperfusion Injury

verfasst von: Nattayaporn Apaijai, Siriporn C. Chattipakorn, Nipon Chattipakorn

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The incidence of obesity with insulin resistance is increasing worldwide. This condition is also known as a risk factor of coronary artery disease and associated with increased arrhythmias, impaired left ventricular function, and increased infarct size during cardiac ischemia-reperfusion (I/R) injury. The proposed mechanisms are due to impaired glucose utilization and pro-survival signaling molecules, and increased inflammatory cytokines, which have been demonstrated in the I/R hearts in various models of obese-insulin resistance. However, the cardiac effects of diets in the I/R heart are still unsettled since several studies reported that high-caloric diet consumption might protect the heart from I/R injury. Although several therapeutic strategies such as anti-diabetic drugs, natural compounds as well as treadmill exercise have been proposed to exert cardioprotection in the I/R heart in obese-insulin resistant animals, some interventions including ischemic post-conditioning failed to protect the heart from I/R injury. In this comprehensive review, reports from both genetic deletion and dietary-induced obese-insulin resistant animal models regarding the effects of obese-insulin resistance on metabolic parameters, cardiac function, infarct size, and molecular mechanisms under I/R injury are summarized. Moreover, the effects of anti-diabetic drugs and other pharmacological interventions on these parameters in an obese-insulin resistant model under I/R injury are also comprehensively summarized and discussed.
Literatur
1.
Jequier E. Obesity. Impairment of energy intake or of energy expenditure. Ann Endocrinol (Paris). 1995;56(2):87–92.
2.
Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N, Chattipakorn SC. Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci. 2011;88(13–14):619–27.PubMedCrossRef
3.
Beck B. Neuropeptide Y, in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1159–85.PubMedCentralPubMedCrossRef
4.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.PubMedCrossRef
5.
Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism. 2008;57(8):1071–7.PubMedCrossRef
6.
West DB, York B. Dietary fat, genetic predisposition, and obesity: lessons from animal models. Am J Clin Nutr. 1998;67(3 Suppl):505S–12.PubMed
7.
Fujita H, Kang M, Eren M, Gleaves LA, Vaughan DE, Kume T. Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression. Circ Res. 2006;98(5):626–34.PubMedCrossRef
8.
Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12(3–4):217–34.PubMedCrossRef
9.
Carillon J, Romain C, Bardy G, Fouret G, Feillet-Coudray C, Gaillet S, et al. Cafeteria diet induces obesity and insulin resistance associated with oxidative stress but not with inflammation: improvement by dietary supplementation with a melon superoxide dismutase. Free Radic Biol Med. 2013;65C:254–61.CrossRef
10.
Liu J, Lloyd SG. High-fat, low-carbohydrate diet alters myocardial oxidative stress and impairs recovery of cardiac function after ischemia and reperfusion in obese rats. Nutr Res. 2013;33(4):311–21.PubMedCentralPubMedCrossRef
11.
Miura T, Tanno M. Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther. 2010;24(3):255–63.PubMedCrossRef
12.
Miura T, Tanno M. The mPTP and its regulatory proteins: final common targets of signalling pathways for protection against necrosis. Cardiovasc Res. 2012;94(2):181–9.PubMedCrossRef
13.
Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol. 2011;106(1):147–62.PubMedCrossRef
14.
Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol. 2008;44(5):915–26.PubMedCrossRef
15.
Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther. 2011;25(1):13–20.PubMedCrossRef
16.
Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, et al. In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther. 2008;325(2):466–74.PubMedCrossRef
17.
Cardenas G, Torres JC, Zamora J, Banos G. Isolated heart function during ischemia and reperfusion in sucrose- fed rats: effect of insulin infusion. Cardiovasc Pathol. 2005;14(5):256–64.PubMedCrossRef
18.
Gundewar S, Calvert JW, Elrod JW, Lefer DJ. Cytoprotective effects of N, N, N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes. Am J Physiol Heart Circ Physiol. 2007;293(4):H2462–71.PubMedCrossRef
19.
Huisamen B, Perel SJ, Friedrich SO, Salie R, Strijdom H, Lochner A. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem. 2011;349(1–2):21–31.PubMedCrossRef
20.
Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol. 2008;294(2):H859–66.PubMedCrossRef
21.
Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res. 2011;50(2):171–82.PubMed
22.
Ooie T, Kajimoto M, Takahashi N, Shinohara T, Taniguchi Y, Kouno H, et al. Effects of insulin resistance on geranylgeranylacetone-induced expression of heat shock protein 72 and cardioprotection in high-fat diet rats. Life Sci. 2005;77(8):869–81.PubMedCrossRef
23.
Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008;295(4):H1580–6.PubMedCentralPubMedCrossRef
24.
Donner D, Headrick JP, Peart JN, du Toit EF. Obesity improves myocardial ischaemic tolerance and RISK signalling in insulin-insensitive rats. Dis Model Mech. 2013;6(2):457–66.PubMedCentralPubMedCrossRef
25.
du Toit EF, Nabben M, Lochner A. A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/reperfusion injury. Basic Res Cardiol. 2005;100(4):346–54.PubMedCrossRef
26.
Huang JV, Lu L, Ye S, Bergman BC, Sparagna GC, Sarraf M, et al. Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. Am J Physiol Heart Circ Physiol. 2013;304(6):H861–73.PubMedCentralPubMedCrossRef
27.
Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, Weber NC. Cyclosporine a administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis. 2010;20(10):706–12.PubMedCrossRef
28.
Jordan JE, Simandle SA, Tulbert CD, Busija DW, Miller AW. Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther. 2003;307(3):1007–11.PubMedCrossRef
29.
Lacerda L, Opie LH, Lecour S. Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes. Exp Diabetes Res. 2012;2012:502654.PubMedCentralPubMedCrossRef
30.
Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res. 2009;84(2):201–8.PubMedCrossRef
31.
Pons S, Martin V, Portal L, Zini R, Morin D, Berdeaux A, et al. Regular treadmill exercise restores cardioprotective signaling pathways in obese mice independently from improvement in associated co-morbidities. J Mol Cell Cardiol. 2013;54:82–9.PubMedCrossRef
32.
Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes. 2002;51(4):1110–7.PubMedCrossRef
33.
Song T, Lv LY, Xu J, Tian ZY, Cui WY, Wang QS, et al. Diet-induced obesity suppresses sevoflurane preconditioning against myocardial ischemia-reperfusion injury: role of AMP-activated protein kinase pathway. Exp Biol Med (Maywood). 2011;236(12):1427–36.CrossRef
34.
Thakker GD, Frangogiannis NG, Zymek PT, Sharma S, Raya JL, Barger PM, et al. Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obesity (Silver Spring). 2008;16(12):2593–600.CrossRef
35.
Wensley I, Salaveria K, Bulmer AC, Donner DG, Du Toit EF. Myocardial structure, function, and ischaemic tolerance in a rodent model of obesity with insulin resistance. Exp Physiol. 2013;98(11):1552–64.PubMedCrossRef
36.
Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979;32(8):563–76.PubMedCrossRef
37.
Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the nutrition committee, American heart association. Circ. 1997;96(9):3248–50.CrossRef
38.
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–35.PubMedCrossRef
39.
40.
41.
Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275(12):9047–54.PubMedCrossRef
42.
Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183–90.PubMedCentralPubMedCrossRef
43.
De Fea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem. 1997;272(50):31400–6.PubMedCrossRef
44.
Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87(1):99–109.PubMedCrossRef
45.
Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33(2):243–57.PubMedCrossRef
46.
van den Brom CE, Bulte CS, Loer SA, Bouwman RA, Boer C. Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism. Cardiovasc Diabetol. 2013;12:42.PubMedCentralPubMedCrossRef
47.
48.
Deng JY, Huang JP, Lu LS, Hung LM. Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats. Am J Physiol Heart Circ Physiol. 2007;293(2):H978–87.PubMedCrossRef
49.
Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta. 2005;1734(2):112–26.PubMedCrossRef
50.
Bopassa JC, Michel P, Gateau-Roesch O, Ovize M, Ferrera R. Low-pressure reperfusion alters mitochondrial permeability transition. Am J Physiol Heart Circ Physiol. 2005;288(6):H2750–5.PubMedCrossRef
51.
Sarti P, Silver RB, Paroli L, Nikonorov I, Blanck TJ. Permeability of rat heart myocytes to cytochrome c. Cell Mol Life Sci. 1999;56(11–12):1061–9.PubMedCrossRef
52.
Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–62.PubMedCrossRef
53.
Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 2008;103(1):82–7.PubMedCrossRef
54.
Tanno M, Bassi R, Gorog DA, Saurin AT, Jiang J, Heads RJ, et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ Res. 2003;93(3):254–61.PubMedCrossRef
55.
Quindry JC, Hamilton KL, French JP, Lee Y, Murlasits Z, Tumer N, et al. Exercise-induced HSP-72 elevation and cardioprotection against infarct and apoptosis. J Appl Physiol (1985). 2007;103(3):1056–62.CrossRef
56.
Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001;3(9):839–43.PubMedCrossRef
57.
Joshy G, Korda RJ, Attia J, Liu B, Bauman AE, Banks E. Body mass index and incident hospitalisation for cardiovascular disease in 158 546 participants from the 45 and Up study. Int J Obes (Lond). 2014;38(6):848–56.CrossRef
58.
Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W, et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012;55(9):2348–55.PubMedCrossRef
59.
Poyraz F, Turfan M, Kocaman SA, Yazici HU, Sen N, Tulmac M, et al. Effect of overweight and obesity on the left ventricular systolic and diastolic functions in patients with acute myocardial infarction. Clin Invest Med. 2012;35(4):E229–36.PubMed
60.
Kadakia MB, Fox CS, Scirica BM, Murphy SA, Bonaca MP, Morrow DA. Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Heart. 2011;97(21):1782–7.PubMedCrossRef
61.
Lee SH, Park JS, Kim W, Shin DG, Kim YJ, Kim DS, et al. Impact of body mass index and waist-to-hip ratio on clinical outcomes in patients with ST-segment elevation acute myocardial infarction (from the Korean acute myocardial infarction registry). Am J Cardiol. 2008;102(8):957–65.PubMedCrossRef
62.
Gastelurrutia P, Pascual-Figal D, Vazquez R, Cygankiewicz I, Shamagian LG, Puig T, et al. Obesity paradox and risk of sudden death in heart failure results from the MUerte subita en insuficiencia cardiaca (MUSIC) study. Am Heart J. 2011;161(1):158–64.PubMedCrossRef
63.
Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol. 2005;98(1):123–31.PubMedCrossRef
64.
Wu AH, Pitt B, Anker SD, Vincent J, Mujib M, Ahmed A. Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. Eur J Heart Fail. 2010;12(6):566–73.PubMedCentralPubMedCrossRef
65.
Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldenberg I. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. Am J Cardiol. 2010;105(5):581–6.PubMedCrossRef
66.
Pingitore A, Di Bella G, Lombardi M, Iervasi G, Strata E, Aquaro GD, et al. The obesity paradox and myocardial infarct size. J Cardiovasc Med (Hagerstown). 2007;8(9):713–7.CrossRef
67.
Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120(10):863–70.PubMedCrossRef
68.
Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38(3):789–95.PubMedCrossRef
69.
Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):93–102.PubMedCrossRef
70.
Khattab AA, Daemen J, Richardt G, Rioux P, Amann FW, Levy R, et al. Impact of body mass index on the one- year clinical outcome of patients undergoing multivessel revascularization with sirolimus-eluting stents (from the arterial revascularization therapies study part II). Am J Cardiol. 2008;101(11):1550–9.PubMedCrossRef
71.
Kosuge M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, et al. Impact of body mass index on in- hospital outcomes after percutaneous coronary intervention for ST segment elevation acute myocardial infarction. Circ J. 2008;72(4):521–5.PubMedCrossRef
72.
Sarno G, Raber L, Onuma Y, Garg S, Brugaletta S, van Domburg RT, et al. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. Am J Cardiol. 2011;108(2):195–201.PubMedCrossRef
73.
Stochmal A, Jasiak-Tyrkalska B, Stochmal E, Huszno B, Kawecka-Jaszcz K. The influence of physical training on metabolic indices in men with myocardial infarction and impaired glucose tolerance. Przegl Lek. 2007;64(6):410–5.PubMed
74.
Wee CC, Girotra S, Weinstein AR, Mittleman MA, Mukamal KJ. The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy. J Am Coll Cardiol. 2008;52(8):620–5.PubMedCrossRef
Metadaten
Titel
Roles of Obese-Insulin Resistance and Anti-Diabetic Drugs on the Heart with Ischemia-Reperfusion Injury
verfasst von
Nattayaporn Apaijai
Siriporn C. Chattipakorn
Nipon Chattipakorn
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2014
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-014-6553-6

Weitere Artikel der Ausgabe 6/2014

Cardiovascular Drugs and Therapy 6/2014 Zur Ausgabe

ORIGINAL ARTICLE

Dodecafluoropentane Emulsion Elicits Cardiac Protection Against Myocardial Infarction Through an ATP-Sensitive K+ Channel Dependent Mechanism

ORIGINAL ARTICLE

Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation

ORIGINAL ARTICLE

Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice

ORIGINAL ARTICLE

Vitamin E Supplementation and Mortality in Healthy People: A Meta-Analysis of Randomised Controlled Trials

ORIGINAL ARTICLE

Angiotensin-(1–7) Modulates Angiotensin II-Induced Vasoconstriction in Human Mammary Artery

LETTER TO THE EDITOR

Is There a Role for Quinazoline-Based α (1)-Adrenoceptor Antagonists in Cardio-Oncology ?

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen